GxP-Compliant AI: Governing Machine Learning in Validated Pharmaceutical Systems

The conversation about AI in pharma tends to stay at 30,000 feet — strategy, competitive positioning, the promise of faster drug development. What gets less attention is the compliance layer underneath all of it. When a machine learning model operates inside a validated GxP environment, it doesn't exist in some separate regulatory space where ordinary rules are suspended. It operates inside the same framework that governs laboratory information management systems, manufacturing execution systems, and electronic batch records: 21 CFR Part 11, ALCOA+ data integrity requirements, computer system validation, and the broader GxP obligations embedded across 21 CFR Parts 210, 211, and 820.

The organizations that are getting this right have stopped treating GxP compliance and AI governance as two different work streams. They are the same work stream. The organizations still running them separately are accumulating compliance debt that FDA inspectors are increasingly equipped to find.

This article is a comprehensive reference for what GxP-compliant AI actually requires — not at the strategic level, but at the level of specific regulatory obligations, practical implementation choices, and the gaps that most programs leave open.

What GxP-Compliant AI Means

GxP is shorthand for the family of Good Practice regulations that govern pharmaceutical manufacturing, clinical research, laboratory operations, and distribution: Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and Good Distribution Practice (GDP), among others. In the US context, these are operationalized primarily through 21 CFR Parts 210 and 211 (drugs), 21 CFR Part 820 (devices), 21 CFR Part 11 (electronic records), and FDA guidance documents. ICH Q10 provides the international quality management system framework that most global pharma companies build their GMP programs around.

When people say "GxP-compliant AI," they mean an AI system that satisfies all applicable GxP requirements for the context in which it operates. A machine learning model used in analytical chemistry to predict compound stability is subject to GLP requirements. A model used to flag out-of-trend results in batch manufacturing is subject to GMP and 21 CFR Part 11. A model used to identify adverse events in clinical trial data is subject to GCP. The "GxP" wrapper is not a single standard — it is the applicable subset of all these standards, determined by where and how the model is used.

What is common across all of them is this: the AI system must be validated, its data must be reliable and auditable, and the organization must be able to demonstrate both to an inspector who has never seen the system before.

FDA's January 2025 draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, and the joint FDA-EMA Guiding Principles of Good AI Practice issued in January 2026 both make the same underlying point explicitly: AI does not replace GxP — it operates within it. That framing matters. It means there is no clean slate for AI in pharma. The existing framework applies, and the compliance question is always about how, not whether.

ALCOA+ and AI-Generated Data

ALCOA+ is FDA's data integrity framework for records in GxP environments. The original ALCOA acronym — Attributable, Legible, Contemporaneous, Original, Accurate — has been extended with additional attributes: Complete, Consistent, Enduring, and Available. FDA operationalized these requirements in its 2018 data integrity guidance, and they apply to every record in a GxP environment, including records generated, processed, or produced by an AI system.

Working through each attribute for a machine learning system is worth doing carefully, because ML introduces specific challenges that traditional computerized systems don't pose.

Attributable

For traditional systems, attributability means knowing who entered or changed a record. For an AI system, attributability extends to the model itself: which version of the model produced this output, trained on which dataset, with which hyperparameters? When an ML model produces a prediction that enters a GxP record — a batch release recommendation, a stability projection, an anomaly detection flag — that record must be attributable to a specific, identified model state. Model versioning is not an optional software engineering practice in a GxP context. It is a data integrity requirement.

The practical implication is that AI systems operating in GxP environments must maintain a model registry that tracks version identifiers, training data snapshots, and the date range during which each model version was active. A batch record that includes a prediction from "the AI model" without specifying which version of the model is not attributable — and therefore not compliant.

Legible

AI outputs must be interpretable by trained personnel — not just technically readable, but understandable enough for a qualified reviewer to evaluate and challenge them. An AI model that produces a numeric score without explanation is not producing a legible record in the GxP sense. This is where explainability requirements, often treated as an AI ethics concern, have a concrete regulatory grounding: GxP records must support human review, and records that can't be interpreted don't support review.

For high-risk AI decisions — batch release, regulatory submission inputs, quality system actions — the output format must include enough context for a reviewer to understand what drove the prediction. This doesn't necessarily require full algorithmic transparency, but it does require that the output be accompanied by the key inputs, confidence indicators, and any flags the model generates.

Contemporaneous

Records must be created at the time of the activity. For AI systems, this means that predictions and outputs must be logged when they are generated — not reconstructed after the fact, not cached and later attributed to the wrong time, and not produced by a model version different from the one active at the time of the underlying event. Systems that batch-process records and backfill AI annotations without timestamp integrity are creating a contemporaneity problem that FDA inspectors specifically look for.

Original

The first capture of data must be preserved. For AI systems that process raw instrument data, sensor outputs, or clinical measurements, the original data must remain intact and unmodified regardless of what the AI model does with it downstream. AI preprocessing — normalization, feature extraction, outlier removal — must be documented and applied in a controlled, auditable way, with the source data remaining available in its original form.

Accurate

Outputs must reflect reality. For ML models, accuracy is a function of training data quality, model performance on validated test sets, and ongoing performance in the deployment environment. An AI system that was accurate at validation but has drifted is no longer producing accurate records. Accuracy as a data integrity requirement implies that organizations must monitor deployed models for performance degradation and have defined thresholds that trigger retraining or decommissioning. This is not a suggestion — it is a condition for maintaining accurate GxP records.

Complete, Consistent, Enduring, Available

These four extended attributes matter in specific ways for AI systems. Completeness requires that AI-generated records include all relevant metadata, not just the primary output. Consistency requires that the same model, applied to the same input under the same conditions, produces the same output — which has implications for determinism and random seed management in ML training. Enduring means records must survive system migrations, software updates, and model replacements without losing integrity. Available means records must be accessible to inspectors and reviewers throughout the required retention period — typically the product lifecycle plus additional years specified in applicable regulations.

Organizations with AI systems that produce GxP records need to work through each ALCOA+ attribute explicitly. The gaps are almost never theoretical. They are specific technical decisions — how model versioning is logged, how outputs are formatted, how performance is monitored — that either satisfy these requirements or don't.

21 CFR Part 11 Requirements for Machine Learning Systems

21 CFR Part 11 applies to electronic records and electronic signatures in FDA-regulated environments. Any AI system that creates, modifies, maintains, archives, retrieves, or transmits records in a GxP context is subject to Part 11 requirements if those records are required by FDA regulations or are submitted to FDA. That covers most ML systems operating in pharmaceutical manufacturing, quality systems, or clinical data management.

The four areas of Part 11 that create specific implementation requirements for ML systems are audit trails, access controls, electronic signatures, and system validation.

Audit Trail Requirements

Part 11 subpart B, section 11.10(e) requires computer systems to use audit trails — computer-generated, time-stamped records of operator actions that create, modify, or delete electronic records. For AI systems, this requirement applies to both the records the AI produces and the AI system itself. An audit trail for a GxP AI system must capture:

Every prediction or output that enters a regulated record, with timestamp and model version identifier
Every manual override or human correction of an AI output, with the identity of the reviewer and the rationale
Every change to the AI system configuration, including model updates, parameter changes, and training data modifications
System access events — who accessed the system, when, and what actions were taken

The audit trail must be computer-generated and not modifiable by users who typically use the system. An AI platform where administrators can edit or delete audit log entries without a higher-level audit of the deletion is not compliant with Part 11 regardless of how sophisticated the AI itself is.

Access Controls

Section 11.10(d) requires limiting system access to authorized individuals. For AI systems, this extends to the model itself: who can query the model in a production GxP context, who can modify model parameters, who can initiate retraining, and who can override model outputs in regulated records. Access controls must be role-based and documented, and the system must enforce them technically rather than relying on procedural controls alone.

The specific concern with ML systems is that they often have multiple access layers — the application interface used by operators, the model infrastructure used by data scientists, and the training pipeline used for model updates — and access controls at one layer don't automatically apply to others. A user who cannot modify an electronic batch record through the front-end application may be able to retrain the model that influences batch release decisions through a back-end ML pipeline. That is a Part 11 access control problem.

Electronic Signatures

Section 11.50 requires that electronic signatures on records be linked to their respective records and that they be executed only by their genuine owners. When AI outputs require human review and approval before entering regulated records — batch release, quality event classification, stability predictions — the electronic signature workflow must be integrated with the AI output in a way that meets Part 11 requirements. The signature must indicate the meaning of the action (review, approval, verification, certification), the date and time, and the printed name of the signer.

The practical issue is that some AI platforms treat human review as a UI step without generating a proper electronic signature as Part 11 defines it. The reviewer clicks "approve" and the AI output enters the system, but there is no signature record that ties the reviewer's identity to that specific prediction on that specific record at that specific time. That gap appears regularly in inspections.

System Validation Under Part 11

Section 11.10(a) requires that systems used to create, modify, maintain, archive, retrieve, or transmit electronic records be validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records. This is the Part 11 validation requirement, and it applies to AI systems alongside all other system validation obligations. See also: Building a Pharma AI Governance Program

Computer System Validation for ML Models

Computer system validation (CSV) for AI and machine learning systems is where the practical complexity lives. Traditional CSV, built around GAMP 5 (Good Automated Manufacturing Practice, 5th edition), assumes that software behaves deterministically: given the same inputs and the same code, the system produces the same outputs. Machine learning breaks that assumption in ways that require fundamentally different validation thinking.

Where ML Fits in GAMP 5

GAMP 5 categorizes software by complexity and configurability:

Category 1: Infrastructure software (operating systems, network tools)
Category 3: Non-configured products (standard spreadsheet software)
Category 4: Configured products (LIMS, MES, ERP platforms)
Category 5: Custom software developed for specific GxP purposes

Machine learning models developed or trained specifically for a GxP application are Category 5 by nature — they are custom software in the most demanding sense of the term. Unlike conventional Category 5 software, however, ML models have parameters that emerge from training rather than being written by developers, and those parameters can change over the model's operational life. GAMP 5 Category 5 validation requirements were designed for fixed-function code. ML requires an extension of that framework, not just its application.

FDA's Computer Software Assurance (CSA) guidance, finalized in September 2025, provides the updated framework. CSA shifts from documentation-heavy scripted testing to a risk-based confidence approach: the rigor of validation must be proportional to the risk the software poses to product quality and patient safety. For high-risk AI systems — those with direct influence on batch release decisions, patient safety signals, or regulatory submissions — this means scripted, pre-specified testing with documented acceptance criteria, equivalent to what GAMP 5 Category 5 has always required. For lower-risk systems, proportionally lighter approaches are acceptable.

The Validation Lifecycle for ML

A validation lifecycle for an ML model in a GxP environment should include at minimum:

Requirements definition: What the model is expected to predict, the population and conditions it applies to, the performance thresholds that define acceptable operation, and the decision context in which outputs will be used
Risk assessment: Classification of the model's risk level based on its potential impact on product quality, patient safety, and regulatory submission integrity — using FDA's Model Influence x Decision Consequence framework or an equivalent structured approach
Training data qualification: Documentation of data sources, preprocessing steps, inclusion and exclusion criteria, and data quality assessments — with ALCOA+ compliance verified for all GxP-sourced training data
Model development documentation: Algorithm selection rationale, architecture decisions, hyperparameter choices, and any exploratory analysis that informed the final model design
Validation testing: Performance evaluation on held-out test data, with pre-specified acceptance criteria for primary performance metrics (accuracy, sensitivity, specificity, AUC, or task-appropriate equivalents) and defined pass/fail thresholds
Prospective validation: For high-risk models, a prospective validation period where the model operates in shadow mode — generating predictions reviewed by qualified personnel but not yet used to drive GxP decisions — before full deployment
Validation summary report: A documented record of validation activities, results, deviations, and the conclusion that the model is suitable for its intended use in the GxP context

The validation summary report becomes a controlled GxP document. It must be maintained, reviewed as part of periodic product reviews, and updated when the model changes significantly enough to require revalidation.

The Change Control Problem

The most distinctive challenge ML poses for CSV is change control. Traditional GxP software change control assumes that changes are discrete, intentional, and implemented by developers who can specify exactly what changed. ML model retraining is different in all three respects: it may be triggered automatically by drift detection, the change affects model parameters throughout the model rather than in a specific code location, and the full magnitude of the change is not known until after training is complete.

This requires a two-stage approach to ML change control. The first stage — the retraining trigger and approval — should follow standard GxP change control procedures: a documented rationale for retraining, approval by qualified personnel, and a plan for evaluating whether the retrained model continues to meet performance requirements. The second stage — post-retraining evaluation — must include a comparison of the new model's performance against the validated baseline, with defined criteria for whether the change constitutes a minor update (no revalidation required), a moderate update (partial revalidation required), or a major update (full revalidation required).

Organizations that retrain models and deploy them without this two-stage change control process are operating outside GxP change management requirements, regardless of whether the technical quality of the retrained model is high. Change control in GxP is a procedural and documentation requirement, not just a technical quality gate.

Audit Trail Requirements for ML Models: Model Versioning, Data Provenance, and Drift Detection

The audit trail requirements for ML systems in GxP environments extend well beyond what Part 11 explicitly specifies for electronic records systems. The full scope of what an auditable ML system requires includes three distinct areas: model versioning, training data provenance, and drift detection records.

Model Versioning

Every deployed version of a GxP AI model must be uniquely identified and its full specification preserved. This includes the model architecture, the serialized model weights or parameters, the software dependencies used during training and inference, and the configuration used to generate predictions in production. A model version identifier should be immutable once assigned — it is a permanent record of a specific model state, not a mutable label.

The model registry must record the deployment history: when each version was deployed to production, when it was retired, and what changed between versions. Inspectors reviewing a GxP record that includes an AI-generated output must be able to trace that output to a specific model version with a documented audit trail of that version's validation status. If that traceability chain cannot be reconstructed, the record's integrity is in question.

Training Data Provenance

For GxP applications, the data used to train an AI model is as much a part of the validation record as the model itself. Training data provenance documentation must include the source of each dataset, the date range of the data, the preprocessing and normalization steps applied, the criteria used to include or exclude records, and any known limitations or quality issues in the source data. If the training data includes GxP records — manufacturing data, laboratory results, clinical measurements — those records must satisfy ALCOA+ requirements in their own right, and the AI training pipeline must preserve their integrity.

This is not a theoretical concern. FDA warning letters have cited data integrity problems in AI training pipelines where source data was modified, mislabeled, or improperly de-identified before being used to train models whose outputs entered regulated records. The problem flows upstream: if the training data is compromised, the model's compliance posture is compromised with it.

Drift Detection

Model drift — degradation in predictive performance as the production environment diverges from the training environment — is a GxP compliance issue, not just a machine learning performance issue. A model that was validated against historical data may perform well for months or years, then gradually produce less accurate predictions as the underlying process, population, or data distribution shifts. If that drift is not detected and corrected, the model begins generating inaccurate GxP records. That is an ALCOA+ accuracy violation.

A GxP-compliant AI governance program must include defined drift detection procedures: what metrics are monitored, what thresholds trigger a review, and what actions are required at each threshold level. Drift monitoring records must be maintained as GxP documentation. The decision to continue operating a drifted model, retrain it, or decommission it must be documented with appropriate review and approval, not made informally by a data science team without a quality record.

Drift detection is not optional maintenance for a GxP AI system. It is the mechanism by which the organization continuously demonstrates that its records remain accurate. Without it, the ALCOA+ accuracy requirement becomes a point-in-time assertion at validation, not an ongoing operational commitment.

A Risk-Based Approach to GxP AI Governance

Not all AI systems in a pharmaceutical organization carry the same regulatory weight. A machine learning model that flags potential adverse events in postmarketing safety surveillance carries different risk than a natural language processing tool used to route internal documents. GxP AI governance must be proportionate — heavier validation, tighter controls, and more rigorous ongoing monitoring for systems with higher risk profiles, with proportionally lighter approaches for lower-risk applications.

FDA's January 2025 draft guidance provides a useful risk calibration matrix built on two dimensions:

Model Influence: The degree to which the AI output directly drives a regulatory or quality decision, versus being one input among many with substantial human review
Decision Consequence: The potential impact of an incorrect decision on patient safety, product quality, or regulatory submission integrity

High-influence, high-consequence systems — AI models that directly determine batch release, generate primary efficacy endpoints in clinical trials, or produce the key data supporting a new drug application — require the most rigorous validation and the most comprehensive ongoing governance. Low-influence, low-consequence systems — AI tools that summarize internal literature or support early-stage research with substantial human review — can be governed with proportionally less formality.

The risk classification decision itself must be documented. An organization cannot simply assert that a model is low-risk without a written rationale that a qualified reviewer has approved. The classification determines the entire governance burden, so it is exactly the kind of decision an FDA inspector will want to see documented with a clear rationale. See also: Pharma AI Risk Assessment Framework

ICH Q9(R1), the revised ICH quality risk management guideline finalized in 2023, provides a framework that maps well onto GxP AI risk assessment: identify the hazard, assess probability and severity of harm, evaluate current controls, and determine whether residual risk is acceptable given the benefits. Applying Q9(R1) rigor to AI risk assessment aligns the AI governance program with established QRM practices that GxP auditors already know how to evaluate.

Practical Implementation Framework: What to Do Now

If you are building or auditing GxP AI compliance from scratch, the sequence of work matters. Here is how I recommend approaching it.

Step 1: Conduct an AI System Inventory

You cannot govern what you have not found. Start with a complete inventory of every AI system — including machine learning models, AI-assisted analytics, and any automated decision tools that use learned models rather than deterministic rules — operating in or adjacent to your GxP environment. For each system, record the application, the data inputs, the outputs that enter GxP records, and a preliminary assessment of regulatory scope.

This inventory frequently reveals systems that the quality organization did not know existed: AI tools implemented by IT or commercial functions that touch quality-adjacent data without having gone through formal qualification. Those systems are a priority for remediation.

Step 2: Apply the Risk Classification

For each inventoried AI system, apply the risk classification framework and document the result. The classification determines the validation approach, the ongoing monitoring requirements, and the documentation burden. Systems that fall into the high-influence, high-consequence category need immediate attention and may require retrospective validation if they are already operating in production without a validation record.

Step 3: Assess ALCOA+ Compliance for AI Data Pipelines

For each AI system, trace the data pipeline from source to AI output to GxP record. At each step, assess compliance with each ALCOA+ attribute. Common gaps include: missing model version attribution in AI-generated records, preprocessing steps that modify original data without documentation, timestamp integrity problems in batch-processed predictions, and drift in deployed models without detection or documentation.

Step 4: Build or Remediate Validation Documentation

For systems without adequate validation records, build the validation package consistent with the risk level and applicable CSA guidance. For systems with existing validation records that predate the CSA framework, assess whether the existing documentation provides sufficient evidence of fitness for purpose, or whether supplemental testing and documentation are needed.

Step 5: Implement Change Control and Drift Monitoring Procedures

These two procedural gaps are the most common in AI programs built by data science teams without GxP quality oversight. Change control procedures for AI models need to be written, approved, and integrated with the existing GxP change control system. Drift monitoring procedures need to specify metrics, thresholds, monitoring frequency, and the quality event process for drift that exceeds defined limits.

Step 6: Train the Quality Organization

Quality assurance personnel who conduct internal audits, write SOPs, and review manufacturing records need working knowledge of how ML systems operate, what their specific GxP risks are, and what evidence to look for when auditing them. AI governance without a quality organization that can evaluate AI-specific compliance is governance in name only.

Cost Considerations: What GxP AI Compliance Costs in Practice

Organizations frequently underestimate the cost of GxP AI compliance because they benchmark against the cost of building the AI system itself, rather than against the cost of validating and maintaining a GxP computerized system. The latter is the right benchmark.

For a single high-risk AI system — one with direct influence on batch release or regulatory submissions — a complete validation package including URS, functional risk assessment, validation plan, IQ/OQ/PQ protocols, execution records, and validation summary report typically represents 20–40% of the development cost of the system itself. That estimate assumes the development team has GxP experience. For teams building their first GxP AI system, the ratio can be higher because the learning curve is steep and the documentation iterations add time.

Ongoing compliance costs for a deployed GxP AI system include:

Drift monitoring: Continuous computation of performance metrics against a maintained reference dataset, with periodic quality reviews of monitoring results. Budget for infrastructure and 4–8 hours of qualified reviewer time per month per high-risk system.
Change control processing: Each retraining cycle that crosses the defined threshold for a formal change control record requires quality review and approval. Budget for 2–8 hours of quality and technical review time per change, depending on scope.
Periodic review: Annual review of validation status, performance history, and continued fit for purpose is standard GxP practice for computerized systems. Budget for 8–16 hours per system annually.
Audit trail review: Periodic review of audit trail completeness and integrity, typically quarterly for high-risk systems.

The aggregate cost for a portfolio of three to five GxP AI systems, maintained to a standard that would survive an FDA inspection, is typically $150,000–$400,000 annually in internal labor and external advisory support, before accounting for any remediation of existing gaps.

These numbers are not a reason to avoid AI in GxP environments — the operational value of well-designed AI systems in pharma manufacturing and quality can far exceed compliance costs. They are a reason to plan for compliance costs before deployment, not discover them after. The organizations that treat GxP compliance as an afterthought in AI development tend to face one of two outcomes: either the AI system never reaches production because it can't pass qualification, or it reaches production and creates inspection liability that costs far more to remediate than proper upfront design would have.

Frequently Asked Questions

Does every AI system in a pharmaceutical company require full GxP validation?

No. GxP validation requirements apply to AI systems that create, modify, maintain, archive, retrieve, or transmit records required by FDA regulations, or whose outputs influence decisions about product quality, patient safety, or regulatory submissions. AI tools used exclusively for non-GxP purposes — HR analytics, financial modeling, general business intelligence — do not carry GxP validation obligations. The key question is always whether and how the system's outputs enter the regulated environment.

How does 21 CFR Part 11 apply to cloud-based AI platforms?

Part 11 requirements apply to the records and the systems that create and maintain them, regardless of whether those systems are on-premises or cloud-based. Organizations using cloud-based AI platforms in GxP contexts must ensure that the platform provides compliant audit trails, access controls, and data integrity protections — or supplement the platform with controls that close any gaps. The platform vendor's SOC 2 certification and HIPAA compliance documentation are not substitutes for Part 11 compliance assessment. They address different requirements.

What happens when a model is retrained? Does it need full revalidation?

Not necessarily. The revalidation scope depends on the nature of the change and the risk level of the system. Minor retraining on updated data with no architecture changes, where performance metrics remain within the validated acceptance criteria, may require only a documented performance comparison against the baseline. Major changes — algorithm changes, significant architecture modifications, or retraining on substantially different data — typically require full or near-full revalidation. The change control procedure must define these thresholds explicitly so that the scope of revalidation is determined by procedure rather than case-by-case judgment.

Can explainable AI (XAI) satisfy the ALCOA+ legibility requirement?

XAI techniques — SHAP values, LIME explanations, attention weights, or similar methods — can contribute meaningfully to satisfying the legibility requirement for GxP AI outputs, provided they are implemented consistently and their outputs are included in the GxP record alongside the primary prediction. However, XAI explanations must themselves be validated to ensure they accurately represent how the model arrived at its prediction, rather than producing plausible-sounding but misleading attributions. Legibility in the ALCOA+ sense is about human reviewers having enough information to evaluate and challenge a record — XAI supports that goal when it is implemented carefully.

What is the relationship between GxP AI compliance and ISO 42001?

ISO 42001 provides the management system infrastructure for AI governance — risk assessment processes, lifecycle management, documentation frameworks, and organizational accountability. GxP compliance provides the specific technical and procedural requirements that those management system processes must satisfy in a regulated pharmaceutical context. The two are complementary: an ISO 42001 AI Management System that embeds GxP requirements into its procedures satisfies both frameworks simultaneously. An ISO 42001 program that does not explicitly address GxP obligations has a gap that FDA inspectors are trained to find.

Where to Start

GxP AI compliance is not a single project with a completion date. It is an ongoing operational discipline that, once built, requires sustained quality management attention to maintain. The organizations that have built it well have two things in common: they started with a clear inventory of what they were governing, and they involved their quality organization from the beginning rather than bringing quality in at the end to ratify decisions already made.

If you are starting now, the most important first step is the AI system inventory. Before writing a single procedure, qualifying a single platform, or building a single validation package, know what you have — which AI systems are operating in your GxP environment, what data they touch, and what decisions they influence. That inventory defines the scope of everything that follows.

The second step is an honest assessment of where your existing systems stand against the requirements in this article: ALCOA+ compliance for AI-generated data, Part 11 controls on AI systems, validation documentation, change control procedures, and drift monitoring. Most organizations find a mix of systems that are in reasonable shape and systems with significant gaps. Prioritizing remediation by risk level — highest-influence, highest-consequence systems first — is both the right compliance strategy and the most defensible one if an inspection arrives before remediation is complete.

The cost of building GxP AI compliance correctly is real. In my experience, it is consistently lower than the cost of remediation after an inspection finding, and it is far lower than the cost of defending an untraceable AI output that influenced a safety-critical decision.

That is the honest calculation.

Last updated: March 2026

Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the founder of Regulated AI Consulting and principal at Certify Consulting. He has guided pharmaceutical, medical device, and biotech organizations through AI governance, quality system design, and regulatory compliance programs. He holds certifications in quality management, pharmaceutical GMP, food safety quality, and regulatory affairs.